FibroGen (NASDAQ:FGEN) Receives “Market Perform” Rating from William Blair

William Blair reiterated their market perform rating on shares of FibroGen (NASDAQ:FGEN) in a report issued on Tuesday,RTT News reports. William Blair also issued estimates for FibroGen’s Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.22) EPS.

Several other brokerages have also recently issued reports on FGEN. StockNews.com began coverage on shares of FibroGen in a research report on Sunday, March 30th. They set a “hold” rating on the stock. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of FibroGen in a research report on Tuesday, March 18th.

FibroGen Price Performance

NASDAQ:FGEN opened at $0.29 on Tuesday. The company has a market cap of $29.70 million, a price-to-earnings ratio of -0.24 and a beta of 0.82. FibroGen has a 1 year low of $0.18 and a 1 year high of $1.82. The stock’s 50 day simple moving average is $0.44 and its two-hundred day simple moving average is $0.42.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $3.14 million during the quarter, compared to the consensus estimate of $24.91 million. As a group, analysts anticipate that FibroGen will post -0.8 EPS for the current year.

Insider Buying and Selling

In other news, Director James A. Schoeneck acquired 250,000 shares of FibroGen stock in a transaction that occurred on Thursday, March 20th. The shares were bought at an average cost of $0.35 per share, with a total value of $87,500.00. Following the transaction, the director now directly owns 323,722 shares of the company’s stock, valued at $113,302.70. This trade represents a 339.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, CEO Thane Wettig acquired 145,000 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was purchased at an average cost of $0.35 per share, with a total value of $50,750.00. Following the purchase, the chief executive officer now owns 543,329 shares of the company’s stock, valued at $190,165.15. The trade was a 36.40 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.98% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On FibroGen

Hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its position in shares of FibroGen by 430.7% during the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 1,358,194 shares during the last quarter. Renaissance Technologies LLC increased its stake in FibroGen by 80.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 605,572 shares during the period. Mackenzie Financial Corp increased its stake in FibroGen by 416.6% in the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 441,083 shares during the period. Squarepoint Ops LLC bought a new stake in FibroGen during the 4th quarter valued at about $205,000. Finally, Two Sigma Advisers LP grew its stake in FibroGen by 18.3% in the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 135,600 shares in the last quarter. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.